You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 131 No. 6, June 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Studies
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

No Detection of Borrelia burgdorferi—Specific DNA in Erythema Migrans Lesions After Minocycline Treatment

Robert R. Muellegger, MD; Natalie Zoechling, MD; H. Peter Soyer, MD; Stefan Hoedl, MD; Ralf Wienecke, MD; Matthias Volkenandt, MD; Helmut Kerl, MD

Arch Dermatol. 1995;131(6):678-682.


Abstract

Background and Design
Early treatment of erythema migrans is important to prevent late complications. Minocycline possesses several attributes, making it potentially useful in the treatment of borrelial infections. In our study, minocycline was administered to 14 patients with erythema migrans. Punch biopsy specimens were obtained from the (affected) skin of all patients before and after therapy. The formalin-fixed, paraffin-embedded specimens were analyzed by polymerase chain reaction for the presence of Borrelia burgdorferi specific DNA.

Results
Polymerase chain reaction assay succeeded in amplifying B burgdorferi—specific DNA from the first biopsy specimen, obtained from the border of erythema migrans before initiating treatment, in eight (57%) of 14 patients. At the end of minocycline therapy, however, polymerase chain reaction analysis disclosed no B burgdorferi—specific DNA in any of the 14 patients. The good clinical response of our patients with erythema migrans substantiates our molecular findings.

Conclusions
The presented polymerase chain reaction data, together with the clinical outcome, indicate that minocycline may be useful for treatment of early Lyme borreliosis.

(Arch Dermatol. 1995;131:678-682)



Author Affiliations

From the Department of Dermatology, Karl-Franzens University, Graz, Austria (Drs Muellegger, Zoechling, Soyer, Hoedl, and Kerl), and the Department of Dermatology, Ludwig-Maximilians University, Munich, Germany (Drs Wienecke and Volkenandt).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical Relevance of Different IgG and IgM Serum Antibody Responses to Borrelia burgdorferi After Antibiotic Therapy for Erythema Migrans: Long-term Follow-up Study of 113 Patients.
Glatz et al.
Arch Dermatol 2006;142:862-868.
ABSTRACT | FULL TEXT  

Diagnosis of Lyme Borreliosis
Aguero-Rosenfeld et al.
Clin. Microbiol. Rev. 2005;18:484-509.
ABSTRACT | FULL TEXT  

Diagnostic Value of PCR for Detection of Borrelia burgdorferi in Skin Biopsy and Urine Samples from Patients with Skin Borreliosis
Brettschneider et al.
J. Clin. Microbiol. 1998;36:2658-2665.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.